Roivant Sciences (STU:87S) Debt-to-Asset : 0.02 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Roivant Sciences Debt-to-Asset?

Roivant Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €9.4 Mil. Roivant Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €86.4 Mil. Roivant Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €5,531.7 Mil. Roivant Sciences's debt to asset for the quarter that ended in Dec. 2024 was 0.02.

Roivant Sciences Debt-to-Asset Historical Data

The historical data trend for Roivant Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Debt-to-Asset Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

0.10

0.11

0.20

0.07

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial														0.07	0.07	0.06	0.01	0.02

Competitive Comparison of Roivant Sciences's Debt-to-Asset

For the Biotechnology subindustry, Roivant Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Roivant Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Roivant Sciences's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(20.142	+	439.628)	/	6644.683
	=	0.07

Roivant Sciences's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.392	+	86.407)	/	5531.689
	=	0.02

Roivant Sciences (STU:87S) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Roivant Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (STU:87S) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ROIV:USA 87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Headlines

No Headlines